SLC37A3 Inhibitors
SMR3B inhibitors pertain to a class of compounds that specifically interact with the human salivary protein known as Submaxillary Gland Androgen Regulated Protein 3B (SMR3B). This protein belongs to the family of proline-rich proteins (PRPs), which are predominantly expressed in the salivary glands and play a role in the physiological functioning of saliva. The inhibitors targeting SMR3B are designed to bind to this protein with high specificity, affecting its natural function. The chemical nature of these inhibitors can be highly varied, encompassing a range of small molecules, peptides, or potentially other macromolecules that have been optimized to engage with the active or binding sites of the SMR3B protein. This interaction is characterized by the affinity and specificity of the inhibitor for its target, and this binding can affect the protein's conformation, stability, or its interaction with other biological molecules.
The development and characterization of SMR3B inhibitors typically involve a deep understanding of the protein's structure and the biochemical pathways it is involved in. The structural elucidation of SMR3B, often through techniques like X-ray crystallography or NMR spectroscopy, provides critical insights into the potential sites that can be targeted by inhibitors. Additionally, biochemical assays are utilized to study the binding kinetics and the inhibitor's impact on the SMR3B protein's function. These compounds are the subject of extensive research to discern their precise mechanism of action at the molecular level, which includes the dynamics of inhibitor binding and the resultant conformational changes in the protein structure.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Probenecid | 57-66-9 | sc-202773 sc-202773A sc-202773B sc-202773C | 1 g 5 g 25 g 100 g | $27.00 $38.00 $98.00 $272.00 | 28 | |
Probenecid is an inhibitor of organic anion transporters (OATs) which can indirectly affect SLC37A3 by altering intracellular levels of substrates that SLC37A3 might transport, leading to reduced transporter activity. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that can inhibit various signaling pathways. It could indirectly affect SLC37A3 function by altering phosphorylation states of proteins involved in transporter regulation. | ||||||
Glyburide (Glibenclamide) | 10238-21-8 | sc-200982 sc-200982A sc-200982D sc-200982B sc-200982C | 1 g 5 g 25 g 100 g 500 g | $45.00 $60.00 $115.00 $170.00 $520.00 | 36 | |
Glyburide is known to inhibit ATP-sensitive potassium channels and could indirectly decrease SLC37A3 activity by modulating cellular energy status and thus influencing transporter function. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $108.00 $245.00 $918.00 $49.00 | 33 | |
Quercetin can inhibit a range of kinases and alter multiple signaling pathways, potentially reducing SLC37A3 activity by affecting regulatory mechanisms of transporter expression or function. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Verapamil is a calcium channel blocker that could indirectly decrease SLC37A3 activity by altering intracellular calcium levels, which may affect calcium-dependent regulatory processes of the transporter. | ||||||
(±)-Sulfinpyrazone | 57-96-5 | sc-202822 sc-202822A | 1 g 5 g | $39.00 $92.00 | 2 | |
Sulfinpyrazone is an inhibitor of organic anion transport and could decrease SLC37A3 activity by competitive inhibition or by altering the transport of endogenous substrates that regulate SLC37A3 function. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $98.00 $315.00 $2244.00 $4396.00 $17850.00 $34068.00 | 3 | |
Colchicine disrupts microtubule polymerization and could indirectly affect SLC37A3 by altering vesicular trafficking processes, potentially affecting the transporter's cellular localization and activity. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $28.00 $88.00 $332.00 | 12 | |
Lovastatin is an HMG-CoA reductase inhibitor that could indirectly affect SLC37A3 by modulating cholesterol synthesis and lipid raft composition, which can influence membrane protein function. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A disrupts Golgi apparatus function and could indirectly affect SLC37A3 by altering the post-translational processing and trafficking of the transporter to the membrane. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporine A is an immunosuppressant that inhibits calcineurin and could indirectly reduce SLC37A3 activity by affecting calcium-dependent signaling pathways that regulate the transporter. | ||||||